Table 1 Clinical features of patients in the eculizumab group
Patient | Age (years old) | Type of cancer | Cumulative dose of gemcitabine (mg) | Time to eculizumab initiation (days) after TMA / Number of injection | Staging of AKI | Hemoglobin level (g/dl) | Platelets count (G/l) | LDH ratio (x normal) | Serum Creatinine level at diagnosis (mg/l) | Hematological response | Renal response | Reduction of creatinine level at the end of the follow-up (mg/l) | Outcome / Time to death or time of last follow-up for still alive patients (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 36 | Ovarian, M+ | 23,760 | 7 d / 4 | 2 | 9.3 | 76 | 1.8 | 18.0 | Yes | Partial | 2.9 | Deceased / 9 m |
2 | 64 | Ovarian, M+ | 16,300 | 7 d / 3 | 3, RRT | 6.9 | 23 | 2.5 | 28.0 | No | No | 0 | Deceased / 1 m |
3 | 54 | Pancreatic, M+ | 31,000 | 44 d / 22 | 2 | 8.5 | 27 | 2.2 | 14.3 | Yes | Partial | 2.5 | Alive / 47 m |
4 | 69 | Pancreatic, M+ | 9040 | 27 d / 3 | 3, RRT | 7.3 | 11 | 2.4 | 18.0 | No | No | 0 | Deceased / 2 m |
5 | 64 | Ovarian, NA | 48,000 | 13 d / 7 | 2 | 9.7 | 130 | 2.2 | 22.5 | Yes | Partial | 7.1 | Deceased / 13 m |
6 | 68 | Pancreatic, M- | 30,000 | 34 d / 14 | 3 | 7.9 | 13 | 4.6 | 17.1 | Yes | Complete | 10.6 | Deceased / 10 m |
7 | 59 | Pulmonary, M+ | 31,200 | 6 d / 5 | 3 | 11.0 | 137 | 1.5 | 31 | Yes | Partial | 6.9 | Alive / 14 m |
8 | 57 | Pulmonary, M+ | 42,500 | 26 d / 4 | 3 | 7.6 | 150 | 1.5 | 76 | Yes | Partial | 16 | Deceased / 3 m |
9 | 52 | Uterine, M+ | 47,000 | 4 d / 2 | 3 | 8.7 | 48 | 2.2 | 70 | Yes | Partial | 47 | Alive / 5 m |
10 | 50 | Pancreatic, M+ | 15,000 | 19 d / 2 | 1 | 8.0 | 139 | 2.2 | 10.2 | Yes | Complete | 3 | Alive / 5 m |
11 | 56 | Ovarian, M+ | 38,000 | 18 d / 3 | 3 | 7.3 | 144 | 3.7 | 24 | Yes | Partial | 10 | Alive / 4 m |
12 | 55 | Ovarian, M+ | 32,000 | 7 d / 4 | 3 | 8.1 | 122 | 1.8 | 64 | Yes | Partial | 29 | Alive / 6 m |